In vitro activity of ceftazidime-avibactam and meropenem-vaborbactam against carbapenem-resistant Enterobacterales in Egyptian Hospitals: A challenge for clinical practice

Microbes and Infectious Diseases /Microbes and Infectious Diseases

Dalia Saad ElFeky, Alaa Reda Awad, Reham Mohammad Raafat Hamed, Manal Mohamed Baddour, Hagar Lotfy Mowafy

Abstract

Background. Ceftazidime-avibactam (CZA) and meropenem-vaborbactam (MVB) are novel therapeutic options for infections caused by carbapenem-resistant Enterobacterales (CRE). Our study aimed to evaluate the in vitro activity of CZA and MVB, against a diverse collection of CRE and to assess the accuracy of the disc diffusion method compared to E-test. Methods. 70 CRE isolated from hospitalized patient...

Keywords

Ceftazidime/avibactam

Carbapenem

Meropenem

Medicine

Avibactam

Microbiology

Carbapenem-resistant enterobacteriaceae

Ceftazidime

Biology

Klebsiella pneumoniae

Antibiotics

Antibiotic resistance

Pseudomonas aeruginosa

Escherichia coli

Bacteria

Biochemistry

Genetics

Gene

2024

Article

Open Access

Institution

Department of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt,

Medical Microbiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

2-Y Citation Average

0.484

DOI

https://doi.org/10.21608/mid.2024.323549.2247

Language

en

Country